Classification Term: 168147

Leukotrienes [FA0302] (ontology term: 3940d9c77f0d1dedd9e9c897e06b66d3)

Leukotrienes [FA0302]

found 54 associated metabolites at sub_class metabolite taxonomy ontology rank level.

Ancestor: Eicosanoids [FA03]

Child Taxonomies: There is no child term of current ontology term.

Leukotriene B4

5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid

C20H32O4 (336.23)


A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway. Chemical was purchased from CAY20110 (Lot 0439924-0).; Diagnostic ions: 335.1, 317.2, 195.1, 129.0, 115.0, 111.5

   

N-Acetyl-leukotriene E4

[5S-[5R*,6S*(s*),7E,9E,11Z,14Z]]-6-[[2-(acetylamino)-2-carboxyethyl]thio]-5-hydroxy-7,9,11,14-eicosatetraenoic acid

C25H39NO6S (481.2498)


N acetyl LTE4 is a minor metabolite of Leukotriene E4 in normal human subjects. (PMID: 2174886) [HMDB] N acetyl LTE4 is a minor metabolite of Leukotriene E4 in normal human subjects. (PMID: 2174886).

   

omega-COOH-LTE4NAc

omega-Carboxy-N-acetyl-LTE4; (7E,9E,11Z,14Z)-(5S,6R)-6-((N-Acetyl)cystein-S-yl)-5-hydroxyeicosa-7,9,11,14-tetraen-1,20-dioate; omega-COOH-LTE4NAc

C25H37NO8S (511.224)


   

Leukotriene C4

5S-hydroxy-6R-(S-glutathionyl),7E,9E,11Z,14Z-eicosatetraenoic acid

C30H47N3O9S (625.3033)


A leukotriene that is (5S,7E,9E,11Z,14Z)-5-hydroxyicosa-7,9,11,14-tetraenoic acid in which a glutathionyl group is attached at position 6 via a sulfide linkage.

   

leukotriene b5

5S,12S-dihydroxy-6Z,8E,14Z,17Z-eicosapentanenoic acid

C20H30O4 (334.2144)


A leukotriene composed of (6Z,8E,10E,14Z,17Z)-icosapentaenoic acid carrying (5S)- and (12R)-hydroxy substituents.

   

LTB4 dimethyl amide

N,N-dimethyl-5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraen-1-amide

C22H37NO3 (363.2773)


   

LTB4 ethanol amide

N-(2-hydroxyethyl)-5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraen-1-amide

C22H37NO4 (379.2722)


   

11-trans-LTC4

5S-hydroxy-6R-(S-glutathionyl)-7E,9E,11E,14Z-eicosatetraenoic acid

C30H47N3O9S (625.3033)


   

11-trans-LTD4

5S-hydroxy-6R-(S-cysteinylglycinyl)-7E,9E,11E14Z-eicosatetraenoic acid

C25H40N2O6S (496.2607)


   

11-trans-LTE4

5S-hydroxy-6R-(S-cysteinyl)-7E,9E,11E14Z-eicosatetraenoic acid

C23H37NO5S (439.2392)


A leukotriene that is the 11-trans-isomer of leukotriene E4.

   

LTB4-d4

5S,12R-dihydroxy-6Z,8E,10E,14Z-eicosatetraenoic acid-d4

C20H28D4O4 (340.2552)


   

14,15-LTC4

15S-hydroxy-14R-(S-glutathionyl)-5Z,8Z,10E,12E-eicosatetraenoic acid

C30H47N3O9S (625.3033)


   

14,15-LTD4

15S-hydroxy,14R-(S-cysteinylglycinyl)-5Z,8Z,10E,12E-eicosatetraenoic acid

C25H40N2O6S (496.2607)


   

14,15-LTE4

15S-hydroxy-14R-(S-cysteinyl)-5Z,8Z,10E,12E-eicosatetraenoic acid

C23H37NO5S (439.2392)


   

Eoxin A4

14S,15S-epoxy-5Z,8Z,10E,12E-eicosatetraenoic acid

C20H30O3 (318.2195)


An oxylipin that is the (14S,15S)-epoxy derivative of (5Z,8Z,10E,12E)-icosa-5,8,10,12-tetraenoic acid.

   

Leukotriene E3

[5S-[5R*,6S*(s*),7E,9E,11Z]]-6-[(2-amino-2-carboxyethyl)thio]-5-hydroxy-7,9,11-eicosatrienoic acid

C23H39NO5S (441.2549)


A leukotriene that is leukotriene E4 in which the non-conjugated double bond has been reduced to a single bond.

   

FA 20:5;O

(5Z,8Z,11Z,14Z)-(17R,18S)-17,18-Epoxyicosa-5,8,11,14-tetraenoic acid

C20H30O3 (318.2195)


A 17(18)-EpETE in which the epoxy group has (17R,18S)-configuration. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

FA 20:4;O3

4-((1S,2S,5R)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyundeca-1,5-dien-1-yl)-3-oxocyclopentyl)butanoic acid

C20H32O5 (352.225)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents

   

FA 20:5;O2

4-((1R,5S)-5-((R,1E,5Z)-3-hydroxyundeca-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)butanoic acid

C20H30O4 (334.2144)


An oxylipin that is the (5S,6S)-epoxy-(15S)-hydroxy derivative of 7E,9E,11Z,13E-icosa-7,9,11,13-tetraenoic acid. D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D000970 - Antineoplastic Agents

   

FA 20:4;O2

(5S,12R,6E,8Z,10E,14Z)-5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid;(5S,6E,8Z,10E,12R,14Z)-5,12-dihydroxyeicosa-6,8,10,14-tetraenoic acid;(6E,8Z)-LTB4;5(S),12(R)-dihydroxy-6(E),8(Z),10(E),14(Z)-eicosatetraenoic acid;5(S),12(R)-dihydroxy-6(E),8(Z),10(E),14(Z)-icosatetraenoic acid;Delta(6)-trans,Delta(8)-cis-LTB4

C20H32O4 (336.23)


   

FA 20:3;O2

(5R,8E,10E,12R,14Z)-5,12-dihydroxyicosa-8,10,14-trienoic acid

C20H34O4 (338.2457)


   

FA 20:3;O4

(S)-5-hydroxy-5-((2S,4S,5S)-4-hydroxy-5-((S,1E,5Z)-3-hydroxyundeca-1,5-dien-1-yl)tetrahydrofuran-2-yl)pentanoic acid

C20H34O6 (370.2355)


   

FA 20:4;O4

4-(3-{[(1S,2S,3S)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]methyl}oxiran-2-yl)butanoic acid

C20H32O6 (368.2199)


D009676 - Noxae > D016877 - Oxidants > D010545 - Peroxides

   

FA 20:5;O3

(5R,6E,8Z,10E,12E,14R,15R,17Z)-5,14,15-trihydroxyicosa-6,8,10,12,17-pentaenoic acid

C20H30O5 (350.2093)


   

Leukotriene E

5S-hydroxy-6R-(S-cysteinyl),7E,9E,11Z,14Z-eicosatetraenoic acid

C23H37NO5S (439.2392)


A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an L-cystein-S-yl group at position 6 (6R).

   

Leukotriene D4

5S-hydroxy-6R-(S-cysteinylglycinyl)-7E,9E,11E,14Z-eicosatetraenoic acid

C25H40N2O6S (496.2607)


A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and a L-cysteinylglycinyl group at position 6 (6R).

   

N-acetyl-LTE4

5S-hydroxy-6R-(S-(N-acetylcysteinyl))-7E,9E,11Z,14Z-eicosatetraenoic acid

C25H39NO6S (481.2498)


   

Leukotriene F4

L-gamma-glutamyl-S-{(1R,2E,4E,6Z,9Z)-1-[(1S)-4-carboxy-1-hydroxybutyl]pentadeca-2,4,6,9-tetraen-1-yl}-L-cysteine

C28H44N2O8S (568.2818)


A leukotriene composed of (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid having (5S)-hydroxy and (6R)-(L-gamma-glutamyl-L-cystein-S-yl) substituents.

   

FA 20:5;O4

(5R,6Z,8E,10E,14Z)-5,20,20-trihydroxy-12-oxoicosa-6,8,10,14-tetraenoic acid

C20H30O6 (366.2042)


   

20-trifluoro-LTB4

5S,12R-dihydroxy-20,20,20-trifluoro-6Z,8E,10E,14Z-eicosatetraenoic acid

C20H29O4F3 (390.2018)


   

Leukotriene A4

5S,6S-epoxy-7E,9E,11Z,14Z-eicosatetraenoic acid

C20H30O3 (318.2195)


A leukotriene that is the (5S,6S)-epoxy derivative of (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid.

   

20-hydroxy-LTE4

5S,20-dihydroxy-6R-(S-cysteinyl),7E,9E,11Z,14Z-eicosatetraenoic acid

C23H37NO6S (455.2341)


   

4,5-LTA4

4R,5R-epoxy-7E,9E,11Z,14Z-eicosatetraenoic acid

C20H30O3 (318.2195)


   

10,11-Dihydro-12R-hydroxy-leukotriene E4

(5S,6R,7E,9E,12S,14Z)-6-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}-5,12-dihydroxyicosa-7,9,14-trienoic acid

C23H39NO6S (457.2498)


   

FA 20:3;O5

(5R,6Z,8E,12R,14Z)-5,12,20,20,20-pentahydroxyicosa-6,8,14-trienoic acid

C20H34O7 (386.2304)


   

FA 20:6;O4

(5R,6Z,8E,10E,14Z)-5-hydroxy-12-oxoicosa-6,8,10,14-tetraenedioic acid

C20H28O6 (364.1886)


   

FA 20:5;O5

(5R,6Z,8E,10E,14Z)-5,20,20,20-tetrahydroxy-12-oxoicosa-6,8,10,14-tetraenoic acid

C20H30O7 (382.1991)


   

14-carboxy-15,16,17,18,19,20-hexanor-leukotriene E3

14-carboxy-15,16,17,18,19,20-hexanor-LTE3;14-carboxy-hexanor-LTE3;14-carboxy-hexanor-leukotriene E3

C17H25NO7S (387.1352)


An icosanoid that is leukotriene E3 in which the terminal octyl group is replaced by a carboxymethyl group.

   

16-carboxy-17,18,19,20-tetranor-leukotriene E3

(5Z,7E,9E,11R,12S)-11-(L-cystein-S-yl)-12-hydroxyhexadeca-5,7,9-trienedioic acid;(5Z,7E,9E,11R,12S)-11-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-12-hydroxyhexadeca-5,7,9-trienedioic acid

C19H29NO7S (415.1665)


An icosanoid that is leukotriene E4 in which the non-conjugated double bond has been reduced to a single bond and four methylene groups have been lost from the resulting carboxyalkyl chain.

   

16-carboxy-Delta(13)-17,18,19,20-tetranor-leukotriene E4

(5Z,7E,9E,11R,12S)-11-(L-cystein-S-yl)-12-hydroxyhexadeca-3,5,7,9-tetraenedioic acid;(5Z,7E,9E,11R,12S)-11-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-12-hydroxyhexadeca-3,5,7,9-tetraenedioic acid

C19H27NO7S (413.1508)


An icosanoid that is leukotriene E4 in which the isolated double bond has migrated into conjugation with the triene moiety and in which four methylene groups have been lost from the resulting carboxyalkyl chain.

   

18-carboxy-19,20-dinor-leukotriene E4

(4Z,7Z,9E,11E,13R,14S)-13-(L-cystein-S-yl)-14-hydroxyoctadeca-4,7,9,11-tetraenedioic acid;(4Z,7Z,9E,11E,13R,14S)-13-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-14-hydroxyoctadeca-4,7,9,11-tetraenedioic acid

C21H31NO7S (441.1821)


An icosanoid that is leukotriene E4 in which two methylene groups are removed from the carboxyalkyl chain attached to the non-conjugated double bond.

   

20-COOH-leukotriene E4

(6Z,9Z,11E,13E,15R,16S)-15-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}-16-hydroxyicosa-6,9,11,13-tetraenedioic acid

C23H35NO7S (469.2134)


   

20-Hydroxy-leukotriene E4

(5S,6R,7E,9E,11Z,14Z)-6-[(2-amino-2-carboxyethyl)sulfanyl]-5,20-dihydroxyicosa-7,9,11,14-tetraenoic acid

C23H37NO6S (455.2341)


   

20-Oxo-leukotriene E4

(5S,6R,7E,9E,11Z,14Z)-6-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}-5-hydroxy-20-oxoicosa-7,9,11,14-tetraenoic acid

C23H35NO6S (453.2185)


   

FA 20:4;O5

(5R,6Z,8E,10E,12S,14Z)-5,12,20,20,20-pentahydroxyicosa-6,8,10,14-tetraenoic acid

C20H32O7 (384.2148)


   

Leukotriene D5

(5R,6S,7E,9E,11Z,14Z,17Z)-6-{[(2R)-2-amino-2-[(carboxymethyl)carbamoyl]ethyl]sulfanyl}-5-hydroxyicosa-7,9,11,14,17-pentaenoic acid

C25H38N2O6S (494.245)


   

N-acetyl-Leukotriene E4

(5R,6S,7E,9E,11Z,14Z)-6-{[(2S)-2-carboxy-2-acetamidoethyl]sulfanyl}-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C25H39NO6S (481.2498)


   

20-carboxy-LTE4

6R-(S-cysteinyl)-(5S)-hydroxy-(7E,9E,11Z,14Z)-eicosatetraenedioic acid

C23H35NO7S (469.2134)


   

18-carboxy-19,20-dinor-N-acetyl-LTE4

(4Z,7Z,9E,11E,13R,14S)-13-(N-acetyl-L-cystein-S-yl)-14-hydroxyoctadeca-4,7,9,11-tetraenedioic acid;(4Z,7Z,9E,11E,13R,14S)-13-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-14-hydroxyoctadeca-4,7,9,11-tetraenedioic acid

C23H33NO8S (483.1927)


   

16-carboxy-17,18,19,20-tetranor-N-acetyl-LTE3

(5Z,7E,9E,11R,12S)-11-(N-acetyl-L-cystein-S-yl)-12-hydroxyhexadeca-5,7,9-trienedioic acid;(5Z,7E,9E,11R,12S)-11-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-12-hydroxyhexadeca-5,7,9-trienedioic acid

C21H31NO8S (457.177)


   

14-carboxy-15,16,17,18,19,20-hexanor-N-acetyl-leukotriene E4

14-carboxy-15,16,17,18,19,20-hexanor-N-acetyl-LTE3;14-carboxy-15,16,17,18,19,20-hexanor-N-acetyl-LTE4;14-carboxy-hexanor-N-acetyl-LTE3;14-carboxy-hexanor-N-acetyl-leukotriene E3

C19H27NO8S (429.1457)


   

16-carboxy-Delta(13)-17,18,19,20-tetranor-N-acetyl-leukotriene E4

(5Z,7E,9E,11R,12S)-11-(N-acetyl-L-cystein-S-yl)-12-hydroxyhexadeca-3,5,7,9-tetraenedioic acid;(5Z,7E,9E,11R,12S)-11-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-12-hydroxyhexadeca-3,5,7,9-tetraenedioic acid

C21H29NO8S (455.1614)


   

Tauro-18-carboxy-19,20-dinor-LTB

5S,12R-dihydroxy-18-oxo-18-(2-sulfoethylamino)octadeca-6Z,8E,10E,14Z-tetraenoic acid

C20H31NO8S (445.177)


   

BML1-E10

(5S,6R,7E,9E,11Z,14Z)-6-(2-acetamido-2-carboxy-ethyl)sulfanyl-5-hydroxy-icosa-7,9,11,14-tetraenoic acid

C25H39NO6S (481.2498)


A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an N-acetyl-L-cystein-S-yl group at position 6 (6R); it is a major bilary metabolite of cysteinyl leukotrienes.